

**TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED**  
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)  
(Company Registration No.91120000103100784F)  
(Incorporated in the People's Republic of China)

---

**UPDATE ON THE PLACEMENT IN RELATION TO THE TEMPORARY USE OF PROCEEDS**

---

***The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.***

The Board refers to the previous announcements by the Company on 12 June 2014, 12 August 2014, 7 January 2015, 28 January 2015, 27 March 2015, 28 April 2015, 8 June 2015, 15 July 2015, 22 July 2015, 14 August 2015, 26 August 2015, 1 September 2015, 7 September 2015, 28 September 2015, 9 October 2015, 15 October 2015, 30 October 2015, 10 November 2015, 17 November 2015, 8 December 2015, 11 December 2015, 23 December 2015, 19 January 2016, 8 March 2016 and 21 March 2016, 26 April 2016, 8 June 2016, 5 July 2016, 12 August 2016, 24 August 2016, 26 August 2016, 29 November 2016, 7 March 2017, 30 March 2017, 13 June 2017, 14 August 2017, 23 August 2017, 24 August 2017, 28 November 2017, 8 January 2018, 30 March 2018, 9 August 2018, 14 August 2018, 24 August 2018, 29 March 2019, 14 August 2019, 23 August 2019, 17 April 2020, 14 August 2020, 30 September 2020, 30 March 2021, 13 August 2021, 8 September 2021, 13 September 2021 and 30 March 2022 (the “**Prior Announcements**”), as well as the circular dated 1 August 2014 (the “**Circular**”) and the circular dated 24 September 2018 in relation to the Placement.

*Unless otherwise defined, all capitalised terms used herein shall bear the same meanings ascribed to them in the Prior Announcements and the Circular.*

Pursuant to the 8<sup>th</sup> Board meeting for the financial year ended 31 December 2021, the Board had considered and passed the resolution approving the Company’s proposed temporary use of RMB350 million from the Net Proceeds for the Company’s cash flow purposes for a period not exceeding 12 months from the date of approval by the Board (the “**FY2021 Temporary Use**”), and the amount of RMB350 million under the FY2021 Temporary Use shall be returned to the Designated Accounts of the Company when this becomes due. Please refer to the announcement made by the Company on 13 September 2021 for further details on the FY2021 Temporary Use.

As at 9 August 2022, the amount of RMB350 million from the Net Proceeds used for the purposes of cash flow of the Company as mentioned above has been returned to the Designated Accounts of the Company, and the Placement Agent has been informed of the same.

**By order of the Board**

Jiao Yan  
Secretary to the Board of Directors  
9 August 2022